The relationship between extended d-dimer elevations and hereditary thrombophilia in COVID-19 patients

Creative Commons License

YALÇIN K. S., YÜCETÜRK H., KASAPOĞLU B., KEKİLLİ M.

Journal of medicine and palliative care (Online), cilt.3, sa.3, ss.147-151, 2022 (Hakemli Dergi)

Özet

Aim: To compare the D-Dimer levels in patients with mild COVID-19 disease with and without hereditary thrombophilia. Material and Method: Factor V Leiden (G1691A) mutation, methylene tetrahydrofolate gene mutation (C677T, A1298C), and PAI-1 (4G5G) and FXIII (V34L) gene mutations were examined in all patients included in the study for various reasons such as recurrent miscarriage and venous embolism. Patients with any mutation were included in the hereditary thrombophilia group, while patients without mutations were included in the control group. D-dimer levels of the patients were also analyzed for the second time at least 25 days after admission. All included patients had received previously at least two doses of the BioNTech-Pfizer or CoronaVac vaccines. Results: A total of 158 patients, 46 (29.1%) male and 112 (70.9%) female, were included in the study. The mean age of the patients included in the study was 39.08 ± 9.09 years. A total of 121 patients, 33 (27.3%) men and 88 (72.7) women, with hereditary thrombophilia were in the first group. A total of 37 patients, 13 (35.1%) male and 24 (64.9%) female, who did not have any mutations, were taken as the control group. Of the patients with hereditary thrombophilia, 47 (38.8%) had Factor V Leiden, 63 (52.1%) had MTHFR gene mutations, 32 (26.4%) had PAI-1 and 12 (9.9%) had FXIII gene mutations. When the D-dimer values of both groups were examined 20-35 days after admission to the hospital, the D-dimer level of the hereditary thrombophilia group was 667.26 ±354.11 while the D-dimer level of the control group was 369.76±173.45 (P=0.031). The D-dimer level of 23 patients in the hereditary thrombophilia group and 2 patients without thrombophilia were found to be above 1000ng/ml when they came for control. Conclusion: It should be kept in mind that if there is prolonged or newly emerging D-dimer elevation in patients who had COVID-19 disease with mild-moderate symptoms, these patients may have hereditary thrombophilia.